{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T17:58:36Z","timestamp":1765994316307},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Association pour la Recherche sur les Infections Virales (ARIV)"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.antiviral.2016.01.015","type":"journal-article","created":{"date-parts":[[2016,1,28]],"date-time":"2016-01-28T09:02:47Z","timestamp":1453971767000},"page":"1-6","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["High conservation of herpes simplex virus UL5\/UL52 helicase-primase complex in the era of new antiviral therapies"],"prefix":"10.1016","volume":"128","author":[{"given":"Marianne","family":"Collot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Rouard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christel","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henri","family":"Agut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Boutolleau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Burrel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2016.01.015_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/095632020701800104","article-title":"Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease","volume":"18","author":"Baumeister","year":"2007","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2016.01.015_bib2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.antiviral.2006.11.006","article-title":"The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB\/c mice infected with herpes simplex virus type 1","volume":"75","author":"Biswas","year":"2007","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.01.015_bib3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/jac\/dkm182","article-title":"Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1","volume":"60","author":"Biswas","year":"2007","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2016.01.015_bib4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.antiviral.2008.04.005","article-title":"Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity","volume":"80","author":"Biswas","year":"2008","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.01.015_bib5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.antiviral.2011.10.016","article-title":"Genotypic characterization of herpes simplex virus DNA polymerase UL42 processivity factor","volume":"93","author":"Burrel","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.01.015_bib6","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1128\/AAC.00669-10","article-title":"Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals","volume":"54","author":"Burrel","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.01.015_bib7","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/jac\/dkq198","article-title":"ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2","volume":"65","author":"Chono","year":"2010","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2016.01.015_bib8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bcp.2012.05.020","article-title":"Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir)","volume":"84","author":"Chono","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2016.01.015_bib9","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nm0402-386","article-title":"Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease","volume":"8","author":"Crute","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2016.01.015_bib10","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1128\/AAC.47.6.1798-1804.2003","article-title":"Oral bioavailability and in\u00a0vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1","volume":"47","author":"Duan","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.01.015_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.drup.2010.11.002","article-title":"Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus","volume":"14","author":"Field","year":"2011","journal-title":"Drug Resist. Updat. Rev. Comment. Antimicrob. Anticancer Chemother."},{"key":"10.1016\/j.antiviral.2016.01.015_bib12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm0402-392","article-title":"New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease","volume":"8","author":"Kleymann","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2016.01.015_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.antiviral.2004.02.007","article-title":"Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase","volume":"64","author":"Liuzzi","year":"2004","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.01.015_bib14","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.jcv.2015.07.250","article-title":"Molecular Beacon-based helicase assay: a way to assess the role of herpes simplex virus (HSV) UL5 helicase mutations in antiviral resistance","volume":"70","author":"Marlet","year":"2015","journal-title":"J.\u00a0Clin. Virol."},{"key":"10.1016\/j.antiviral.2016.01.015_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0022-2836(85)90320-1","article-title":"Sequence determination and genetic content of the short unique region in the genome of herpes simplex virus type 1","volume":"181","author":"McGeoch","year":"1985","journal-title":"J.\u00a0Mol. Biol."},{"issue":"Pt 1","key":"10.1016\/j.antiviral.2016.01.015_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1099\/0022-1317-68-1-19","article-title":"DNA sequence and genetic content of the HindIII l region in the short unique component of the herpes simplex virus type 2 genome: identification of the gene encoding glycoprotein G, and evolutionary comparisons","volume":"68","author":"McGeoch","year":"1987","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.antiviral.2016.01.015_bib17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/rmv.1787","article-title":"Antiviral drug resistance in herpesviruses other than cytomegalovirus","volume":"24","author":"Piret","year":"2014","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2016.01.015_bib18","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1128\/AAC.00977-15","article-title":"Sequence analysis of herpes simplex virus 1 Thymidine kinase and DNA polymerase genes from over 300 clinical isolates from 1973 to 2014 finds novel mutations that may be relevant for development of antiviral resistance","volume":"59","author":"Schmidt","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.01.015_bib19","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.1128\/JVI.72.9.6979-6987.1998","article-title":"Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex","volume":"72","author":"Spector","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.01.015_bib20","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/jis019","article-title":"ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study","volume":"205","author":"Tyring","year":"2012","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.01.015_bib21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1056\/NEJMoa1301150","article-title":"Helicase-primase inhibitor pritelivir for HSV-2 infection","volume":"370","author":"Wald","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2016.01.015_bib22","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1517\/14728222.2013.827663","article-title":"The DNA helicase-primase complex as a target for herpes viral infection","volume":"17","author":"Weller","year":"2013","journal-title":"Expert Opin. Ther. Targets"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216300195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216300195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T13:46:33Z","timestamp":1600091193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354216300195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":22,"alternative-id":["S0166354216300195"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.01.015","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High conservation of herpes simplex virus UL5\/UL52 helicase-primase complex in the era of new antiviral therapies","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}